SCHEMBL20338323

SCHEMBL20338323

Fc1cc2nc(-c3cnnc(SC(F)(F)F)c3)n(C3CC3)c2cc1F

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 20/20 1.00
CYP11B2 P19099 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20338429 0.86 CYP11B2 (1.00) CYP11B1CYP11B2
SCHEMBL20338216 0.84 CYP11B2 (1.00) CYP11B1CYP11B2
SCHEMBL20338364 0.83 CYP11B2 (1.00) CYP11B1CYP11B2
SCHEMBL20338380 0.83 CYP11B2 (0.78) CYP11B1CYP11B2
SCHEMBL20338288 0.83 CYP11B1 (1.00) CYP11B1CYP11B2
SCHEMBL20338297 0.81 CYP11B2 (1.00) CYP11B1CYP11B2
SCHEMBL20338242 0.81 CYP11B2 (1.00) CYP11B1CYP11B2
SCHEMBL20340031 0.81 CYP11B1 (0.68) CYP11B1CYP11B2
SCHEMBL20338300 0.80 CYP11B2 (0.76) CYP11B1CYP11B2
SCHEMBL20338290 0.80 CYP11B2 (0.76) CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260097034-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LTD (HK) 2026-04-09 US claimed
US-12458642-B2 Metalloenzyme inhibitor compounds CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2025-11-04 US claimed
EP-4311577-A2 METALLOENZYME INHIBITOR COMPOUNDS Ji Xing Pharmaceuticals Hong Kong Limited (HK) 2024-01-31 EP claimed
CN-110691598-A Metalloenzyme inhibitor compounds 赛列尼蒂治疗(百慕大)有限公司 2020-01-14 CN claimed
US-20190008861-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2019-01-10 US claimed
US-10085984-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) 2018-10-02 US claimed
US-20260097034-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LTD (HK) 2026-04-09 US disclosed
US-12458642-B2 Metalloenzyme inhibitor compounds CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2025-11-04 US disclosed
EP-4311577-A2 METALLOENZYME INHIBITOR COMPOUNDS Ji Xing Pharmaceuticals Hong Kong Limited (HK) 2024-01-31 EP disclosed
EP-3562487-B1 METALLOENZYME INHIBITOR COMPOUNDS JI XING PHARMACEUTICALS HONG KONG LTD (HK) 2023-11-29 EP disclosed
US-20210322409-A1 METALLOENZYME INHIBITOR COMPOUNDS SELENITY THERAPEUTICS (BERMUDA), LTD. (BM) 2021-10-21 US disclosed
US-20210322409-A1 METALLOENZYME INHIBITOR COMPOUNDS SELENITY THERAPEUTICS (BERMUDA), LTD. (BM) 2021-10-21 US disclosed
US-11040034-B2 Metalloenzyme inhibitor compounds PHASEBIO PHARMACEUTICALS, INC. (US) 2021-06-22 US disclosed
US-11040034-B2 Metalloenzyme inhibitor compounds PHASEBIO PHARMACEUTICALS, INC. (US) 2021-06-22 US disclosed
CN-110691598-A Metalloenzyme inhibitor compounds 赛列尼蒂治疗(百慕大)有限公司 2020-01-14 CN disclosed
US-20190008861-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2019-01-10 US disclosed
US-10085984-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) 2018-10-02 US disclosed
US-20180185362-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2018-07-05 US disclosed
US-20180185362-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2018-07-05 US disclosed
US-20180185362-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2018-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12458642-B2 Metalloenzyme inhibitor compounds CYP11B2, CYP11B1, HSD11B2 CYP11B1 2/4885CYP11B2 1/4885
US-20180185362-A1 METALLOENZYME INHIBITOR COMPOUNDS SOD1, RNASE1, FECH CYP11B1 370/4885CYP11B2 405/4885
US-20260097034-A1 METALLOENZYME INHIBITOR COMPOUNDS CPN1, TPP1, DPP4 CYP11B1 481/4885CYP11B2 500/4885
US-20210322409-A1 METALLOENZYME INHIBITOR COMPOUNDS SOD1, RNASE1, FECH CYP11B1 370/4885CYP11B2 405/4885
US-11040034-B2 Metalloenzyme inhibitor compounds SOD1, RNASE1, FECH CYP11B1 370/4885CYP11B2 405/4885
US-20190008861-A1 METALLOENZYME INHIBITOR COMPOUNDS SOD1, RNASE1, FECH CYP11B1 370/4885CYP11B2 405/4885
US-10085984-B2 Metalloenzyme inhibitor compounds SOD1, RNASE1, FECH CYP11B1 370/4885CYP11B2 405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.